Document Detail

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
MedLine Citation:
PMID:  22954177     Owner:  NLM     Status:  Publisher    
Introduction: Over the last two decades, experimental and clinical data suggest a therapeutic benefit of cannabis-based medicines for a variety of multiple sclerosis (MS) symptoms. Clinical trials, both with synthetic or plant-derived cannabinoids, have demonstrated clinical efficacy of cannabinoids for the treatment of spasticity, neuropathic pain and bladder dysfunction. Nabiximols , a 1:1 mix of delta-9-tetrahydrocanabinol and cannabidiol extract from cloned chemovars, was licensed in the UK in 2010 and has also been approved in other European countries and Canada. The European Federation of Neurological Societies recommends that cannabis should be used only as a second or third line treatment in central neuropathic pain. Areas covered: After a brief discussion of the endocannabinoid system, this review focuses on the use of cannabis to improve MS symptoms. More specifically, the authors have analyzed clinical studies on cannabis-based medicine extract (CBME), in particular nabiximols, in spasticity, as well as pain, and bladder dysfunction in MS. The authors have considered the large randomized controlled trials examining the psychological effects associated with cannabinoids use as well as long-term follow-up studies. Expert opinion: Despite a number of trials with very promising results, there are still concerns related to relative paucity of data on long-term safety. Also, the long-term efficacy information in terms of the control of symptoms of a disease in which the natural history is progression is sparse. Therefore, further studies are required to improve the current knowledge of nabiximols.
Giulio Podda; Cris S Constantinescu
Related Documents :
23092837 - Morphologic and functional changes in the temporomandibular joint and stomatognathic sy...
23989797 - Lateral wedge insoles as a conservative treatment for pain in patients with medial knee...
22958597 - Modifying patterns of movement in people with low back pain -does it help? a systematic...
24715667 - Preventing and managing aberrant drug-related behavior in primary care: systematic revi...
17544127 - Assessing pain in persons with dementia: relationships among the non-communicative pati...
25275577 - Effect of intravenous lidocaine on postoperative recovery of patients undergoing mastec...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-7
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  -     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Clinical Neurology , C Floor South Block, Queen's Medical Centre, Nottingham, NG7 2UH , UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The complete mitochondrial genome of Megophrys shapingensis (Amphibia, Anura, Megophryidae).
Next Document:  Effects Of Acute And Chronic Atorvastatin On Cadioprotection Of Ischemic Postconditioning In Isolate...